Why the study?
Does bivalirudin reduce the composite of death, MI, revascularization, and major bleeding compared to heparin in patients undergoing PCI?
Does bivalirudin reduce the composite of death, MI, revascularization, and major bleeding compared to heparin in patients undergoing PCI?
In a pooled analysis of PCI patients, bivalirudin provided superior ischemic protection and significantly fewer bleeding complications compared to heparin at 48 hours.
No takes yet. Share an insight, caveat, or question.
Supports bivalirudin over heparin in PCI; extends RCT evidence with pooled confirmation of early benefit.
Ebrahimi et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: